Abcellera Biologics INC 8-K filings

AbCellera Biologics Inc. announced the pricing of an oversubscribed public offering of common shares and pre-funded warrants, raising approximately $200 million to fund its internal pipeline and general corporate purposes.

AbCellera Biologics Inc. announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, showing significant reductions in vasomotor symptoms and a favorable tolerability profile.

AbCellera Biologics Inc. announced it will release top-line data from its Phase 2 trial for ABCL635, a non-hormonal treatment for menopausal vasomotor symptoms, on August 10, 2026, followed by an investor call.

AbCellera Biologics Inc. announced a strategic collaboration with Vertex Pharmaceuticals Incorporated to discover, develop, and commercialize multispecific T-cell engagers for autoimmune diseases.

AbCellera Biologics Inc. announced the appointment of Dr. Lynn Seely as an independent director to its Board of Directors.

AbCellera Biologics Inc. and Jazz Pharmaceuticals plc have entered into a preclinical research collaboration to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

AbCellera Biologics shareholders re-elected Class III directors and ratified the appointment of Ernst & Young LLP.

AbCellera Biologics Inc. has appointed veteran medical oncologist Dr. Victor Sandor as an independent director to its Board of Directors.

AbCellera Biologics Inc. announced its Q1 2026 financial results and positive interim Phase 1 data for its potential first-in-class antibody, ABCL635, targeting the neurokinin 3 receptor for menopausal vasomotor symptoms.

AbCellera Biologics Inc. announced significant revenue growth and pipeline advancements for the full year 2025, transitioning to a clinical-stage biotech with substantial liquidity.

AbCellera Biologics Inc. announced the dosing of first patients in the Phase 2 portion of its ABCL635 clinical trial for moderate-to-severe vasomotor symptoms due to menopause, with top-line results expected in Q3 2026.

AbCellera Biologics Inc. announced a global settlement of its patent litigation with Bruker Corporation, including an upfront payment of $36 million and future royalties.

AbCellera Biologics Inc. announced the dismissal of KPMG LLP and the engagement of Ernst & Young LLP as its new independent registered public accounting firm, effective after the 2025 fiscal year audit.

AbCellera Biologics Inc. announced the appointment of Dr. Stephen Quake as an independent director, while Dr. Andrew Lo resigned from the board.

AbCellera Biologics Inc. announced its third quarter 2025 financial and operational results, reporting an increased net loss alongside progress in clinical trials and substantial liquidity.

AbCellera Biologics Inc. announced the appointment of Dr. Sarah Noonberg as its first Chief Medical Officer, signaling a strategic focus on advancing its clinical pipeline.

AbCellera Biologics Inc. announced strong Q2 2025 financial results, including a significant revenue increase and reduced net loss, alongside the initiation of two Phase 1 clinical trials for ABCL635 and ABCL575, marking its transition to a clinical-stage biotechnology company.

AbCellera Biologics Inc. announced that its shareholders approved all three proposals at the Annual Meeting held on June 12, 2025, including the re-election of two Class II directors, the ratification of KPMG LLP as independent auditors, and the advisory approval of executive compensation.

AbCellera Biologics Inc. announced it has received a No Objection Letter from Health Canada, authorizing its Clinical Trial Application for ABCL575, an investigational antibody for moderate-to-severe atopic dermatitis, with a Phase 1 trial anticipated to begin in Q3 2025.

AbCellera has received a No Objection Letter from Health Canada to initiate a Phase 1 clinical trial for ABCL635, a non-hormonal treatment for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.

AbCellera's patent for microfluidic cell culture technology has been affirmed as valid by the U.S. Court of Appeals for the Federal Circuit, rejecting Bruker's challenge.

AbCellera reported its Q1 2025 financial results, including a net loss of $45.6 million, and announced ABCL635, a potential first-in-class antibody for vasomotor symptoms associated with menopause.

AbCellera announces its full year 2024 financial results, highlighting its transition to a clinical-stage biotech with advancements in its internal pipeline and significant investments in capabilities.

AbCellera Biologics Inc. reports that Dr. Veronique Lecault has transitioned from Chief Operating Officer to Chief Technology Officer, effective February 18, 2025.

AbCellera announced its Q3 2024 financial results, highlighting progress in its internal pipeline, facility consolidation, and strategic partnerships.

AbCellera announced its Q2 2024 financial results, highlighting progress in its internal pipeline and partner programs, including upcoming clinical trial applications and strategic collaborations.

AbCellera Biologics Inc. held its annual shareholder meeting on June 13, 2024, where shareholders elected two Class I directors, ratified the appointment of KPMG LLP as the independent auditor, and approved executive compensation.

AbCellera reported its Q1 2024 financial results, highlighting progress in strategic partnerships and internal pipeline development, with a focus on its T-cell engager platform.

Peter Thiel will resign from AbCellera's Board of Directors, effective March 7, 2024, with Dr. Andrew Lo appointed to the Nominating and Corporate Governance Committee.

AbCellera's full year 2023 results show a significant revenue decrease compared to 2022, alongside a strategic shift towards internal programs and partnerships.